Takeda’s seizure drug fails to meet main goal in late-stage studies

(Reuters) – Japan’s Takeda said on Monday its experimental drug to treat epileptic disorders failed to meet the main goal in two late-stage studies.

The drug, soticlestat, was being tested in adult and pediatric patients with Dravet syndrome and Lennox-Gastaut syndrome.

These are severe forms of epilepsy characterized by frequent, prolonged seizures, that typically becomes apparent during infancy or early childhood.

Takeda plans to discuss with regulatory authorities to determine next steps.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)